The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome

European Journal of Clinical Pharmacology

Volumn 69, Issue 12, 2013, Pages 2065-2072

  Lankheet, Nienke A G ^a   Huitema, Alwin D R ^a   Mallo, Henk ^b   Adriaansz, Sandra ^b   Haanen, John B A G ^b   Schellens, Jan H M ^b,c   Beijnen, Jos H ^a,c   Blank, Christian U ^b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Skin exposure; Skin toxicity; Sunitinib; Sweat; Sweat patch

Indexed keywords

N DEETHYLSUNITINIB; SUNITINIB;

ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; EXPLORATORY RESEARCH; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERHIDROSIS; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SEASONAL VARIATION; SUMMER; SWEATING; TRANSDERMAL PATCH; TREATMENT DURATION;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HAND-FOOT SYNDROME; HUMANS; INDOLES; MALE; MIDDLE AGED; PYRROLES; SEASONS; SWEAT;

EID: 84892365226     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1579-4     Document Type: Article

References (26)

1. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329-1338
2. Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16-24
3. Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501-513
4. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66(2):357-371
5. Abrams TJ, Murray LJ, Pesenti E et al (2003) Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2(10):1011-1021
6. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2(5):471-478
7. Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24(1):25-35
8. Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1):327-337
9. Murray LJ, Abrams TJ, Long KR et al (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20(8):757-766
10. Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME (2008) Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 16(6):557-566
11. Lacouture ME, Wu S, Robert C et al (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13(9):1001-1011
12. Lacouture ME, Reilly LM, Gerami P, Guitart J (2008) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19(11):1955-1961
13. Jacobi U, Waibler E, Schulze P et al (2005) Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 16(7):1210-1211
14. Lipworth AD, Robert C, Zhu AX (2009) Hand-foot syndrome (handfoot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77(5):257-271
15. Rivier L (2000) Techniques for analytical testing of unconventional samples. Bailliere's Clin Endocrinol Metab 2010:147-165
16. Lankheet NA, Blank CU, Mallo H et al (2011) Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient. J Anal Toxicol 35(8):558-565
17. Gore ME, Szczylik C, Porta C et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10(8):757-763
18. Staiger H, Laschewski G, Gratz A (2012) The perceived temperature-a versatile index for the assessment of the human thermal environment. Part A: scientific basics. Int J Biometeorol 56(1): 165-176
19. KNMI (2012). Royal Dutch Meteorological Institute (KNMI): monthly climatology overviews (ambient temperature, humidity). Available at: http://www.knmi.nl/klimatologie/maand-en-seizoensoverzichten/Date accessed: July 17, 2012
20. Hartley M, Crook D (2012) Pharm Chek drugs of abuse sweat patch (Training manual). Available at: http://www.pharmchem.com/pharmchem/files/download-files/ Patch-Training-Manual-Rev-Feb-2012-Final.pdf Date accessed: July 17, 2012. Product Information
21. Lankheet NA, Steeghs N, Rosing H et al (2013) Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring. Ther Drug Monit 35(2):168-176
22. Rorabacher DB (1991) Statistical treatment for rejection of deviant values: critical values of Dixon's "Q" parameter and related subrange ratios at the 95% confidence level. Anal Chem 63(2):139-146
23. Bex A, van der Veldt AA, Blank C et al (2009) Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 27(4):533-539
24. van der Veldt AA, Boven E, Helgason HH et al (2008) Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 99(2):259-265
25. Jain L, Gardner ER, Figg WD, Chernick MS, Kong HH (2010) Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy 30(1):52-56
26. European Medicines Agency (EMA). Sutent: EPAR-scientific discussion. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Scientific-Discussion/human/000687/WC500057733.pdf Date accessed: July 17, 2012. 10-1-2007